Literature DB >> 19110022

HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines.

J C Kapteyn1, A M Porre, E J P de Rond, W B Hessels, M A Tijms, H Kessen, A M E Slotboom, M A Oerlemans, D Smit, J van der Linden, P Schoen, J L G Thus.   

Abstract

The haemagglutinin (HA) content is an important specification of influenza vaccines. Recently, a reversed-phase high performance liquid chromatography (RP-HPLC) method for quantification of HA in PER.C6 cell culture-based whole virus vaccines has been reported, having a high sensitivity, precision, broad range, and high sample throughput [Kapteyn JC, Drissi Saidi M, Dijkstra R, Kars C, Tjon CMS-K, Weverling GJ et al. Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Vaccine 2006;24:3137-44]. This RP-HPLC assay is based on measuring the peak area of HA1, the hydrophilic subunit of HA, which turned out to be proportional to the amount of HA analyzed. Here, we present data demonstrating that this RP-HPLC method is also highly suitable for HA quantification of active and BPL- or formaldehyde-inactivated egg-based and MDCK cell-based whole virus samples, including egg allantoic harvest, and in final (monovalent) subunit vaccines, including those for pandemic H5N1 strains and for virosomal vaccines. In addition, the RP-HPLC assay was demonstrated to be a very powerful tool in the early stages of seasonal influenza vaccine production, when homologous serial radial immunodiffusion (SRID) reagents are not yet available, enabling fast and reliable viral growth studies in eggs in order to select the best growing virus strains or reassortants for the production of the seasonal trivalent influenza vaccine. Because of its high sensitivity, the RP-HPLC assay has shown its enormous value in supporting small scale MDCK-based (H5N1) influenza virus production models. Finally, the observed differences between HA1 molecules from various HA subtypes in UV absorbance, FLD response, and in the actual retention times in RP-HPLC are discussed in relation to the primary structure of the HA1 molecules studied.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19110022     DOI: 10.1016/j.vaccine.2008.11.113

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

1.  Bringing influenza vaccines into the 21st century.

Authors:  Ethan C Settembre; Philip R Dormitzer; Rino Rappuoli
Journal:  Hum Vaccin Immunother       Date:  2013-12-30       Impact factor: 3.452

Review 2.  Downstream processing and chromatography based analytical methods for production of vaccines, gene therapy vectors, and bacteriophages.

Authors:  Petra Kramberger; Lidija Urbas; Aleš Štrancar
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.

Authors:  Surender Khurana; Christopher Larkin; Swati Verma; Manju B Joshi; Juan Fontana; Alasdair C Steven; Lisa R King; Jody Manischewitz; William McCormick; Rajesh K Gupta; Hana Golding
Journal:  Vaccine       Date:  2011-06-23       Impact factor: 3.641

4.  Development and application of a reversed-phase high-performance liquid chromatographic method for quantitation and characterization of a Chikungunya virus-like particle vaccine.

Authors:  Anastasija Shytuhina; Pavlo Pristatsky; Jian He; Danilo R Casimiro; Richard M Schwartz; Van M Hoang; Sha Ha
Journal:  J Chromatogr A       Date:  2014-06-19       Impact factor: 4.759

5.  Evaluation of Mycoplasma inactivation during production of biologics: egg-based viral vaccines as a model.

Authors:  Selwyn A Wilson David; Dmitriy V Volokhov; Zhiping Ye; Vladimir Chizhikov
Journal:  Appl Environ Microbiol       Date:  2010-03-12       Impact factor: 4.792

6.  Development of the H3N2 influenza microneedle vaccine for cross-protection against antigenic variants.

Authors:  Yura Shin; Jeonghun Kim; Jong Hyeon Seok; Heedo Park; Hye-Ran Cha; Si Hwan Ko; Jae Myun Lee; Man-Seong Park; Jung-Hwan Park
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

7.  A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide.

Authors:  Changgui Li; Bozena Jaentschke; Yingli Song; Junzhi Wang; Terry D Cyr; Gary Van Domselaar; Runtao He; Xuguang Li
Journal:  Nat Protoc       Date:  2010-01       Impact factor: 13.491

8.  Solid bioneedle-delivered influenza vaccines are highly thermostable and induce both humoral and cellular immune responses.

Authors:  Peter C Soema; Geert-Jan Willems; Klaas van Twillert; Gijsbert van de Wijdeven; Claire J Boog; Gideon F A Kersten; Jean-Pierre Amorij
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

9.  A novel synthetic receptor-based immunoassay for influenza vaccine quantification.

Authors:  Anwar M Hashem; Caroline Gravel; Aaron Farnsworth; Wei Zou; Michelle Lemieux; Kangwei Xu; Changgui Li; Junzhi Wang; Marie-France Goneau; Maria Merziotis; Runtao He; Michel Gilbert; Xuguang Li
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

Review 10.  Analytical technologies for influenza virus-like particle candidate vaccines: challenges and emerging approaches.

Authors:  Christine M Thompson; Emma Petiot; Alexandre Lennaertz; Olivier Henry; Amine A Kamen
Journal:  Virol J       Date:  2013-05-04       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.